Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina. more
Time Frame | FENC | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.82% | -2.06% | -0.55% |
1-Month Return | 40.27% | -1.92% | 2.72% |
3-Month Return | 8.43% | -10.4% | 7.66% |
6-Month Return | -14.89% | -4.6% | 10.15% |
1-Year Return | -43.29% | 4.06% | 27.53% |
3-Year Return | 34.44% | 1.94% | 32.31% |
5-Year Return | -4.79% | 36.48% | 89.2% |
10-Year Return | 136.82% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 170.00K | 170.00K | 1.53M | 21.25M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":0.8,"profit":true},{"date":"2021-12-31","value":0.8,"profit":true},{"date":"2022-12-31","value":7.22,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | - | - | - | 86.00K | 1.26M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":6.83,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | - | 170.00K | - | 1.45M | 19.99M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":0.85,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":7.25,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | - | 100.00% | - | 94.40% | 94.08% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":94.4,"profit":true},{"date":"2023-12-31","value":94.08,"profit":true}] |
Operating Expenses | 13.01M | 18.05M | 17.22M | 24.04M | 32.76M | [{"date":"2019-12-31","value":39.71,"profit":true},{"date":"2020-12-31","value":55.11,"profit":true},{"date":"2021-12-31","value":52.57,"profit":true},{"date":"2022-12-31","value":73.37,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (13.01M) | (17.89M) | (17.22M) | (22.59M) | (12.77M) | [{"date":"2019-12-31","value":-1300900000,"profit":false},{"date":"2020-12-31","value":-1788500000,"profit":false},{"date":"2021-12-31","value":-1722300000,"profit":false},{"date":"2022-12-31","value":-2258900000,"profit":false},{"date":"2023-12-31","value":-1277100000,"profit":false}] |
Total Non-Operating Income/Expense | 485.00K | (539.00K) | (195.00K) | (2.06M) | (6.17M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-111.13,"profit":false},{"date":"2021-12-31","value":-40.21,"profit":false},{"date":"2022-12-31","value":-424.12,"profit":false},{"date":"2023-12-31","value":-1271.55,"profit":false}] |
Pre-Tax Income | (12.78M) | (18.11M) | (17.35M) | (23.71M) | (16.05M) | [{"date":"2019-12-31","value":-1277500000,"profit":false},{"date":"2020-12-31","value":-1810900000,"profit":false},{"date":"2021-12-31","value":-1734600000,"profit":false},{"date":"2022-12-31","value":-2371400000,"profit":false},{"date":"2023-12-31","value":-1604500000,"profit":false}] |
Income Taxes | (315.00K) | (187.00K) | 110.00K | 1.13M | 1.00 | [{"date":"2019-12-31","value":-28,"profit":false},{"date":"2020-12-31","value":-16.62,"profit":false},{"date":"2021-12-31","value":9.78,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (12.46M) | (17.92M) | (17.46M) | (24.84M) | (16.05M) | [{"date":"2019-12-31","value":-1246000000,"profit":false},{"date":"2020-12-31","value":-1792200000,"profit":false},{"date":"2021-12-31","value":-1745600000,"profit":false},{"date":"2022-12-31","value":-2483900000,"profit":false},{"date":"2023-12-31","value":-1604500100,"profit":false}] |
Income From Continuous Operations | (12.78M) | (18.11M) | (17.35M) | (23.71M) | (20.22M) | [{"date":"2019-12-31","value":-1277500000,"profit":false},{"date":"2020-12-31","value":-1810900000,"profit":false},{"date":"2021-12-31","value":-1734600000,"profit":false},{"date":"2022-12-31","value":-2371400000,"profit":false},{"date":"2023-12-31","value":-2022000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (12.46M) | (17.92M) | (17.46M) | (24.84M) | (16.05M) | [{"date":"2019-12-31","value":-1246000000,"profit":false},{"date":"2020-12-31","value":-1792200000,"profit":false},{"date":"2021-12-31","value":-1745600000,"profit":false},{"date":"2022-12-31","value":-2483900000,"profit":false},{"date":"2023-12-31","value":-1604500000,"profit":false}] |
EPS (Diluted) | (0.64) | (0.77) | (0.67) | (0.90) | (0.61) | [{"date":"2019-12-31","value":-64,"profit":false},{"date":"2020-12-31","value":-77,"profit":false},{"date":"2021-12-31","value":-67,"profit":false},{"date":"2022-12-31","value":-90,"profit":false},{"date":"2023-12-31","value":-61,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
FENC | |
---|---|
Cash Ratio | 5.42 |
Current Ratio | 7.80 |
Quick Ratio | 7.64 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
FENC | |
---|---|
ROA (LTM) | 2.70% |
ROE (LTM) | -1005.59% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
FENC | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.09 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.09 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
FENC | |
---|---|
Trailing PE | NM |
Forward PE | 11.93 |
P/S (TTM) | 3.15 |
P/B | 57.93 |
Price/FCF | NM |
EV/R | 2.99 |
EV/Ebitda | 48.83 |
Fennec Pharmaceuticals Inc (FENC) share price today is $5.66
Yes, Indians can buy shares of Fennec Pharmaceuticals Inc (FENC) on Vested. To buy Fennec Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in FENC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Fennec Pharmaceuticals Inc (FENC) via the Vested app. You can start investing in Fennec Pharmaceuticals Inc (FENC) with a minimum investment of $1.
You can invest in shares of Fennec Pharmaceuticals Inc (FENC) via Vested in three simple steps:
The 52-week high price of Fennec Pharmaceuticals Inc (FENC) is $11.92. The 52-week low price of Fennec Pharmaceuticals Inc (FENC) is $3.96.
The price-to-earnings (P/E) ratio of Fennec Pharmaceuticals Inc (FENC) is
The price-to-book (P/B) ratio of Fennec Pharmaceuticals Inc (FENC) is 57.93
The dividend yield of Fennec Pharmaceuticals Inc (FENC) is 0.00%
The market capitalization of Fennec Pharmaceuticals Inc (FENC) is $167.07M
The stock symbol (or ticker) of Fennec Pharmaceuticals Inc is FENC